The investor euphoria for Incyte’s experimental cancer drug is hard to rationalize – STAT
|
The investor euphoria for Incyte’s experimental cancer drug is hard to rationalize
STAT Depending on who you ask, the cancer immunotherapy accounts for $10 billion to $12 billion of Incyte’s current $27 billion market value. That’s a huge bet on a single drug not yet approved. If epacadostat were a stand-alone company, it would be worth … |
|
Cancer immunotherapy proves itself in earlier-stage disease
Reuters MADRID (Reuters) – Cancer doctors are widening the net for immunotherapy, a hot new class of drugs that enlist the body’s defenses in the fight against tumors. The latest research shared with 23,000 experts at Europe’s top oncology meeting shows how … |
|
Manchester Royal Eye Hospital delivers gene therapy for the first time
AOP Manchester Royal Eye Hospital (MREH) has delivered gene therapy for the first time as a treatment for X-linked retinitis pigmentosa (XLRP). The hospital is part of a ‘ground breaking’ pilot that involves more than 24 patients receiving a modified RPGR … |
New Atlas |
Changing a flower’s color with the CRISPR gene-editing tool
New Atlas It often takes years of careful cross-breeding for horticulturalists to turn flowers certain colors, but scientists can dig right in and change them at a genetic level much faster. Using the CRISPR-Cas9 gene-editing tool, scientists have changed the … |
|
CAR–T in the Courts
Genetic Engineering & Biotechnology News A patent fight continues over engineered chimeric antigen receptors for T–cell therapies (CAR-T). In December 2016, the Patent Trial and Appeal Board upheld a patent for a specific design of a chimeric antigen receptor (CAR) designed by researchers at … |